更新于：2024-11-01

Obesity, Metabolically Benign

代谢良性肥胖

更新于：2024-11-01

基本信息

别名

Benign Obesity, Metabolically、Healthy Obesity, Metabolically、Metabolically Benign Obesity

+ [5]

简介

A sub-PHENOTYPE of obese individuals who have a risk for CARDIOVASCULAR DISEASES between that of healthy individuals with normal weight and unhealthy individuals with obesity.

关联

项与代谢良性肥胖相关的药物

Piromelatine

靶点

5-HT1A receptor x 5-HT1D receptor x MTNR1A x MTNR1B

作用机制

5-HT1A receptor拮抗剂 [+3]

在研机构

Neurim Pharmaceuticals Ltd. [+1]

原研机构

Neurim Pharmaceuticals Ltd.

在研适应症

阿尔茨海默症 [+2]

非在研适应症

入睡和睡眠障碍

最高研发阶段临床2/3期

首次获批国家/地区-

首次获批日期1800-01-20

DR10624

靶点

FGF21R x GCGR x GLP-1R

作用机制

FGF21R激动剂 [+2]

在研机构

浙江道尔生物科技有限公司 [+1]

原研机构

浙江道尔生物科技有限公司

在研适应症

高甘油三酯血症 [+7]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

MET-3

靶点-

作用机制

细菌替代物 [+1]

在研机构-

原研机构

Nubiyota LLC

在研适应症-

非在研适应症

高甘油三酯血症 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与代谢良性肥胖相关的临床试验

NCT06355544 / Not yet recruitingN/A

Integrative and Personalized Lifestyle Approach to Reduce Low-Grade Inflammation in People at Risk of Cardiometabolic Diseases

The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
The main questions it aims to answer are:
Whether it is possible to predict low-grade inflammation
What are the medical, biological, and lifestyle variables related to low-grade inflammation?
Participants will be asked to:
Attend a general medical visit to collect vital signs, anthropometric measurements, and collect blood samples.
Complete questionnaires and collect a stool sample at home.

开始日期2024-04-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

[+4]

NCT06297928 / RecruitingN/AIIT

Metabolomics and Bariatric Surgery in Patients With Metabolically Unhealthy Obesity: Advancing Precision Medicine for the Treatment of Obesity

The goal of this observational study is to investigate metabolic changes in individuals undergoing bariatric surgery, specifically focusing on those with obesity and varying metabolic health statuses. The main questions it aims to answer are:
Can metabolic markers predict the transition from metabolically unhealthy obesity to metabolically healthy obesity after bariatric surgery?
How do metabolic profiles change in individuals with metabolically healthy obesity after bariatric surgery?
What are the metabolic differences between individuals with metabolically healthy and unhealthy obesity before and after bariatric surgery?
Participants will undergo routine evaluations and blood tests before and after bariatric surgery. These tests will include assessments of metabolic health markers and sampling of blood plasma for metabolomic analysis. The study will study changes in metabolic profiles between individuals who transition to metabolically healthy obesity and those who remain metabolically unhealthy after surgery.

开始日期2024-01-01

申办/合作机构

Consorci Mar Parc de Salut de Barcelona

NCT05933707 / RecruitingN/AIIT

Effect of Small Extracellular Vesicles From Adipose Tissue on Insulin Action

The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.

开始日期2023-06-08

申办/合作机构

Washington University School of Medicine

100 项与代谢良性肥胖相关的临床结果

登录后查看更多信息

100 项与代谢良性肥胖相关的转化医学

登录后查看更多信息

0 项与代谢良性肥胖相关的专利（医药）

登录后查看更多信息

390

项与代谢良性肥胖相关的文献（医药）

2024-12-01·Public Health

Prevalence and inequalities of obesity and associated complications in China: A multicentre nationwide survey

Article

作者: Wang, Jiangang ; Wang, Tao ; Ting, Peng ; Hong, Min ; Fu, Min ; Zheng, Zhian ; Lin, Yanhui ; Lin, Ren

OBJECTIVESObesity is a risk factor for chronic diseases. The prevalence of obesity is rapidly increase and a significant social inequality exists. This study aimed to analyse obesity prevalence and complications in different regions and occupations in China.STUDY DESIGNMulticentre cross-sectional study.METHODSData from 62,893 adults in 10 Chinese provinces were collected in 2022. Measures included body mass index (BMI), metabolic status and complications. Analysis was stratified by gender, age, region and occupation, with results adjusted for age and gender.RESULTSThe average BMI was 23.81 ± 3.42 kg/m², with overweight and obesity prevalence at 34.29 % and 11.24 %, respectively. North China had the highest obesity rate (27.93 %), followed by West (26.64 %), South (25.37 %) and East China (20.06 %). Functionaries (e.g. as civil servants, corporate executives) had higher BMI than employees or intellectual professionals, while workers had higher BMI than farmers. Intellectual professionals had the lowest rates of metabolically healthy obesity (MHO) at 4.90 % and metabolically unhealthy obesity (MUO) at 3.47 %, followed by employees (MHO 6.63 %, MUO 4.45 %) and functionaries (MHO 6.74 %, MUO 4.94 %). Workers had the highest MHO prevalence rate at 8.51 %, while farmers had the highest MUO rate at 6.16 %. Obesity-associated complications were 1.5-3 times more common among obese individuals than those in the normal BMI category, with inequality observed across different occupational groups.CONCLUSIONSIn China, a large number of adults with obesity have poor metabolic health, highlighting the importance of considering metabolic status when addressing obesity-related chronic diseases. Addressing the inequality in obesity rates can inform public health strategies to tackle the increasing problem of obesity and its associated complications in China.

2024-11-01·Nature Reviews Endocrinology

Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications

Review

作者: Schulze, Matthias B ; Stefan, Norbert

The concept of metabolic health, particularly in obesity, has attracted a lot of attention in the scientific community, and is being increasingly used to determine the risk of cardiovascular diseases and diabetes mellitus-related complications. This Review assesses the current understanding of metabolically healthy obesity (MHO). First, we present the historical evolution of the concept. Second, we discuss the evidence for and against its existence, the usage of different definitions of MHO over the years and the efforts made to provide novel definitions of MHO. Third, we highlight epidemiological data with regard to cardiovascular risk in MHO, which is estimated to be moderately elevated using widely used definitions of MHO when compared with individuals with metabolically healthy normal weight, but potentially not elevated using a novel definition of MHO. Fourth, we discuss novel findings about the physiological mechanisms involved in MHO and how such knowledge helps to identify and characterize both people with MHO and those with metabolically unhealthy normal weight. Finally, we address how the concept of MHO can be used for risk stratification and treatment in clinical practice.

2024-11-01·International Journal of Obesity

Cushing’s syndrome screening with the 1-mg dexamethasone suppression test in metabolically healthy and unhealthy obesity phenotypes

Article

作者: Unsal, Ilknur Ozturk ; Akhanli, Pinar ; Kizilgul, Muhammed ; Hepsen, Sema ; Sencar, Muhammed Erkam ; Bostan, Hayri ; Cakal, Erman ; Gul, Umran

AbstractBackgroundThe ongoing debate regarding the need for screening Cushing’s syndrome (CS) in patients with obesity continues. The objectives of this study were to establish the prevalence of CS in the population with obesity and assess how metabolic health status influences cortisol levels following the 1 mg dexamethasone suppression test (DST).MethodsThis retrospective study included 1008 patients with obesity who underwent screening with the 1 mg DST for CS. These patients were categorized into two groups as metabolically healthy obesity (MHO) and unhealthy obesity (MUO).ResultsOut of the 1008 patients, 779 (77.3%) belonged to the MUO group. Within the entire study cohort, 12 (1.2%) patients exhibited a cortisol level of ≥ 1.8 after the 1 mg DST. Cortisol levels following the 1 mg DST were also significantly higher in the MUO group than in the MHO group (p = 0.001). Among these 12 patients, 11 were presenting a MUO phenotype. Hypercortisolism was definitively diagnosed in two patients, resulting in an overall prevalence of 0.2%. The 1 mg DST demonstrated a specificity of 99% and 100% sensitivity for screening for CS.ConclusionsWhile the 1 mg DST is a practical screening test for CS with high specificity in obesity, the number of CS cases detected remains relatively low. Therefore, it may be more reasonable and applicable to screen patients with MUO phenotype rather than all individuals with obesity.